(MENAFN- Swissinfo)
Español
(es)
Roche declara la guerra a la obesidad con una adquisición multimillonaria
Milestone payments of up to $400 million can also be made. According to Monday's announcement, Carmot Therapeutics is privately held and has in its pipeline product candidates that can be used to treat obesity in patients with and without diabetes. They are all based on the novel GLP-1 mechanism of action, which has recently been the subject of a lot of media attention.
Recently, the drug Wegovy caused a stir. It is a product from the Danish pharmaceutical company Novo Nordisk. It contains the active ingredient semaglutide, which promotes weight loss in people who are very overweight.
Wegovy, for example, has to be injected under the skin once a week. In people with obesity without additional diabetes, Wegovy therapy can lead to a weight reduction of up to 15 percent over a treatment period of 18 months. In principle, Wegovy increases the feeling of satiety, which reduces the calories consumed because patients simply have less hunger and appetite.
Other products in this area include Ozempic, also from Novo Nordisk, or Eli Lilly's diabetes drug Mounjaro, which also ensures weight loss.
With the takeover of Carmot, Roche is now adding three important GLP-1 product candidates to its portfolio. Two of the candidates will be tested to treat obesity in patients with and without type 2 diabetes, while the third will be used to treat type 1 diabetes patients who are overweight or obese.
Send us your input
Do you have more questions about this story?
Your contribution Our journalists will take your contribution on board for their coverage and may follow up with you via email. If you have questions, get in touch . Your contribution... How we work
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles. You can find them hereExternal link .
If you want to know more about how we work, have a look hereExternal link , and if you have feedback on this news story please write to ...External link .
End of insertion External Content Your subscription could not be saved. Please try again. Almost finished... We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you. Daily news
Get the most important news from Switzerland in your inbox.
Daily
Email
The SBC Privacy Policy provides additional information on how your data is processed.
I consent to the use of my data for the SWI swissinfo newsletter.
Articles in this story
Do you have more questions about this story?
In compliance with the JTI standards
More: SWI swissinfo certified by the Journalism Trust Initiative
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at ... .
MENAFN04122023000210011054ID1107533460
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.